

Cloud Computing in a Regulated Pharma Environment

Issues and Concerns about Data Security and Safety

Prof. Dr. Thomas Staedter

Introduction

Technologies and Trends



Cloud Computing

- an emerging technology that has a broad, cross-industry relevance
- · transformational and high impact in potential
- a topic that has gained momentum in the last years.


[Cf. Avanade, 2011; Forrester Research, 2011; Gartner, 2011]

"With Cloud Computing against cancer and Alzheimer"

[Handelsblatt, 2011]

Gartner Hype Cycle 2013





3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

3

Introduction

Risk and Responsibility in a Hyper connected World



Findings from the research include:

"... Moreover, **security concerns** are already making companies delay implementation of cloud and mobile technology capabilities."

"In a best-case scenario, in which a solid cyber resilience ecosystem accelerates digitization, the private and public sectors see greater use of public cloud technologies, with enhanced security capabilities for non-critical workloads. Better use of private clouds handles critical workloads. Both public and private clouds continue to offer similar features. Enhanced security for private clouds comes at minimal performance penalty, and at a more noticeable performance penalty for public clouds. Under this case, cloud computing has the potential to create US\$ 3.72 trillion in value by 2020."

[World Economic Forum, Jan. 2014]

Problem Statements



- 1. Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?
- 2. What is the impact on systems operation in Regulatory Affairs?
- What are the issues and concerns about data security and safety with cloud publishing solutions?
- How to define and address the risks to non- compliance and potential auditing shortfalls with cloud solutions?
- What/Which are the possibilities for linking cloud solutions and in-house hosted systems?
- Are there any performance and reliability concerns of cloud solutions in the publishing environment which should be considered? How can those be addressed?
- What are the remaining challenges for cloud solutions in publishing?

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

5

Topics, Definitions and State of the Art

Cloud Computing



"... is a model for enabling ubiquitous, convenient, on-demand network access to a shared pool of configurable computing resources (e.g., networks, servers, storage, applications, and services) that can be rapidly provisioned and released with minimal management effort or service provider interaction."

[Mell, P. & Grance, T., 2011]

From a user perspective, the provided abstracted IT infrastructure seems distant and opaque, like in a "cloud".

Cloud Computing compared to conventional IT



"The appearance of infinite computing **resources available on demand**, quickly enough to follow load surges, thereby eliminating the need for cloud computing users to plan far ahead for provisioning.

The elimination of an up-front commitment by cloud users, thereby allowing companies to start small and increase hardware resources only when there is an increase in their needs.

The ability to pay for use of computing resources on a short-term basis as needed (for example, processors by the hour and storage by the day) and release them as needed, thereby rewarding conservation by letting machines and storage go when they are no longer useful."

[Armbrust, M. et al., 2010]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

FO

Topics, Definitions and State of the Art **Cloud Advantages**

Kelton Research Survey

- · Organized by market research firm Kelton Research on behalf of Avanade
- 573 interviews with managers, IT executives and department managers in Germany and 17 other countries

Cloud Advantages

- · Cost Benefits (58%)
- · Flexible IT (52%)
- Simplified IT processes (36%)
- Focus on key operational issues (27%)
- Scalability (24%)
- Productivity and employee satisfaction (20%)

[Avanade, 2011]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment



Surveys show that 80% of businesses already using the cloud reported 10%-20% lower IT costs, while 20% of them reported savings rising to 30% or above.

The Commission will work with the support of ENISA and other relevant bodies to assist the development of an EU-wide voluntary certification schemes in the area of cloud computing (including data protection) and establish a list of such schemes by 2014.

[European Commission, Sept. 2012]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

10

Topics, Definitions and State of the Art **2013 State of the Enterprise Cloud**



Report by Verizon Enterprise Solutions

- company data between January 2013 and June 2013
- · examines cloud adoption and usage trends

Cloud Adoption, Usage Increases

- cloud-based storage has increased by 90% during the time studied and
- cloud- based memory by 100%, driven by the shift of business-critical applications to the cloud.
- enterprises have increased their average monthly spend on cloud by 45%

Additional remarks

- as more critical applications reside in the cloud uptime and availability are now essential
- security and related compliance requirements are driving an increased focus on the cloud provider's data center.

[FEI, Oct. 2013]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment





3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

12

Topics, Definitions and State of the Art **Business Process Flexibility**



... is an important benchmark to assess the performance of companies in volatile markets

[Gebauer et al., 2008]


Can be approached by SOA (Service Oriented Architectures)

simpler, more timely and cost-efficient way of $% \left(1\right) =\left(1\right) +\left(1\right) +\left($

... by Cloud Computing

Licensing and Deployment Perspective





3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

14

Topics, Definitions and State of the Art 1st Conclusion for Question 1



Cloud Computing as a Business and IT Service Model offers:

- · Multi-Tenant Support
- · Fast Provisioning and Self-Service-Model
- · Simple and faster HW- and SW-Maintenance awa Updates & Patches
- · On-Demand Service / Pay per Use / Pay as you Go
- · Geographic Distribution, Partition Tolerance
- · Availability, Reliability and Scalability
- Measurability and Verifiability / Testability / QoS and SLAs
- · Freedom from Licensing / License Clarity

RIM Summary - Managing Regulatory Information as a Corporate Asset



Companies lower their overall total cost of ownership

- aggressive publishing outsourcing within the pasts two vears
- analysis of alternative solution hosting concepts such as Software as a Service (SaaS) and cloud computing
- increase in the investigation and use of the SaaS model in small and mid-tier companies
- · but, a significant adoption level is still a few years away.

Distinct stages of investment / believe that industry is transitioning into stage two:

- Information consolidation to realize a true global authoritative source (2008 2015)
- Incorporate health authority and industry data standards; improve usability (2011
 – 2015)
- Cloud or SaaS based options (2014 2018)

[Gens & Brolund, 2013]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

16

Topics, Definitions and State of the Art

Publishing Trends* which could be supported by SaaS



Usability standpoint


- 1. data entry flexibility by role or location
- 2. device independent consumption (laptop, table, smartphone, and desktop),
- 3. simple user interface, smart reporting and analytics, and
- connectivity regardless of location (mobility which is more a general business requirement).

Publishing sourcing trend

dramatic as companies are moving aggressively towards outsourcing or internal work redistribution to internal sites in India and China.

[*cf. Gens & Brolund, 2013]





 3X increase in overall activity as measured by product + pilot + investigating since 2011

[Gens & Brolund, 2013]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

18



2nd Conclusion for Question 1

Cloud technologies gained momentum in pharmaceutical companies

- Increase in the investigation and use of the SaaS model in small and mid-tier
- Transition to Cloud or SaaS based options (2014 2018)

[cf. Gens & Brolund, 2013]

RIM Cloud application Status

- · Few vendors offering true cloud services tailored to support the requirements of regulatory information management.
 - [Gens & Brolund, 2013]
- Solutions available from: Aris Global, Assured PV, EMC D2, EXTEDO, Lorenz, Mission3, Qumas, Samarind, Veeva (vendor selection in alphabetical order; there is no claim for completeness)
- · Partnerships between DMS and Publishing providers

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Problem Statement 1



The concepts of Cloud Computing are applicable to pharmaceutical firms, because of:

- · ever-growing datasets
- · unpredictable traffic patterns
- · demand for faster response times
- · reduced time to market
- · Business Continuity
- · reducing the capital exposure of 'owning' IT
- ..

Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?

Yes

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

20

Topics, Definitions and State of the Art

Problem Statements



1. Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?

2. What is the impact on systems operation in Regulatory Affairs?

- What are the issues and concerns about data security and safety with cloud publishing solutions?
- How to define and address the risks to non- compliance and potential auditing shortfalls with cloud solutions?
- What/Which are the possibilities for linking cloud solutions and in-house hosted systems?
- Are there any performance and reliability concerns of cloud solutions in the publishing environment which should be considered? How can those be addressed?
- What are the remaining challenges for cloud solutions in publishing?

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Cloud-specific security risks



These relate mainly to:

- Multi-tenancy and shared resources character of cloud computing (that means that the same physical infrastructure will often serve many different customers of a cloud provider).
- Client cedes control of security to some extent to the service provider, making it important to be able to assess whether the cloud service provider complies with the security requirements.

Recommendations and measures

- Certification schemes will play an important role because they help providers signal compliance to prospective users in a reliable way (e.g. ISO 27001).
- Increase security (for non-IT security experts) by leaving security issues to the professionals working for the cloud service provider [cf. European Commission, Sept. 2012; Tsvihun, 2010]
- · Certification for Cloud providers
 - EuroCloud SaaS-Star Audit Certificate [Giebichenstein/Weiss, 2011]
 - ISO/IEC 27001

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

2

Issues and concerns about data security and safety

Related Surveys



[Avanade Survey, 2011] Security concerns: 63%

Not enough know-how for the use of cloud technologies: 63%

Trust in the provider of cloud-based services: 38%

Costs that might be associated with the introduction of such technologies: 38%

[IDC Survey, 2011]


Governance: 34% Compliance: 24%

Performance and Availability of Services: 24%

Issues and concerns about data security and safety

BITKOM Cloud Monitor 2014





3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

24

Issues and concerns about data security and safety

Security Concerns



Cloud Security Alliance Survey:

- 1 from 10 non US members have cancelled their contracts with US based Cloud providers
- 50% probably won't chose an US based Cloud provider

[CSA, 2011]

Information Technology & Innovation Foundation

 The U.S. cloud computing industry stands to lose \$22 to \$35 billion over the next three years as a result of the recent revelations about the NSA's electronic surveillance programs.

[Castro, Aug. 2013]

Forrester Research

- "The Cost of PRISM Will Be Larger Than ITIF projects"
- "... the total could still add another \$10 billion to the overall losses for this market"

[Staten, Aug. 2013]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Problem Statements



1. Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?

2. What is the impact on systems operation in Regulatory Affairs?

- What are the issues and concerns about data security and safety with cloud publishing solutions?
- How to define and address the risks to non- compliance and potential auditing shortfalls with cloud solutions?
- What/Which are the possibilities for linking cloud solutions and in-house hosted systems?
- Are there any performance and reliability concerns of cloud solutions in the publishing environment which should be considered? How can those be addressed?
- What are the remaining challenges for cloud solutions in publishing?

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

26

Risks to non- compliance and potential auditing shortfalls **Data Protection Compliance**



Relevant legal frameworks:

- EU: Data Protection Directive (95/46/EC)
- UK: Data Protection Act 1998
- · US: Health Insurance Portability and Accountability Act 1996

Suggested approach for new cloud services:

- Customer should conduct a full due diligence examination (if possible) prior to entering into any arrangement.
- The results of the risk analysis should be captured in the contractual documents between the parties
- The extent of the clauses will depend on the nature and risk of data being placed in the cloud.

[cf. Wilson & Bray, 2013]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Cloud users from Europe should consider ...



European legislation

- · High risk of penalties on data privacy
- Data Processing Agreement (Directive 95/46/EC of the European Parliament) / Commission pursuant to Section 11 BDSG
- Individual written provisions set out in Section 11(2) Nos 1 to 10 of the Federal Data Protection Act [Bundesdatenschutzgesetz – BDSG]
- EU Data Protection Act which offers additional "Joint Controllership" clause to cover responsibility of subcontractors

Third countries (e.g. US):

- · Directive 95/46/EC of the European Parliament and of the Council
- Standard contractual clauses for the transfer of personal data to processors established in third countries

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

28

Risks to non-compliance and potential auditing shortfalls

Compliance with HIPAA



Recommendations

- Check if you are covered by this security rule (health care provider or health care clearinghouse)
- Put safeguards in place to ensure appropriate protection of electronic protected health information

Requirements for covered entities

- Ensure the confidentiality, integrity, and availability of all e-PHI they create, receive, maintain
 or transmit;
- Identify and protect against reasonably anticipated threats to the security or integrity of the information;
- · Protect against reasonably anticipated, impermissible uses or disclosures; and
- Ensure compliance by their workforce. [HHS.gov]

SaaS suppliers should:

- Consider amending the design of the SaaS software to make it more appropriate for dealing with PHI and to support compliance with HIPAA obligations
- Prohibit PHI from being uploaded into and stored on the SaaS system
- · Specific contracts/SLAs

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment



Compliance with all Applicable Data Privacy Laws (example)

- Directive 95/46/EC as implemented in the law of any EU Member State which is applicable to the provision of the hosting services, together with any other laws in any other country which is applicable to the provision of the hosting services described herein relating to the privacy and protection of personally identifiable information or protected health information (including, as applicable, the Health Insurance Portability and Accountability Act of 1996 (HIPAA) Privacy and Security Rules, 45 C.F.R. Parts 160-164, and the Health Information Technology for Economic and Clinical Health Act (HITECH), P.L. No. 111-005, Part I, Title XIII, Subpart D, 13401-13409, and U.S. state privacy laws) are collectively referred to as the "Applicable Data Privacy Laws").
- Each party warrants to the other that it will store, handle, use, disclose and Process all Personal Data, and all personally identifiable information and protected health information which it obtains from the other party pursuant to this Agreement in compliance with all Applicable Data Privacy Laws.

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

30

Risks to non-compliance and potential auditing shortfalls Validation Challenges in a Cloud Environment



Quality paradigm shift

- "... from quality processes contained within a regulated company to a model where quality is achieved as a result of partnership between the regulated company, service providers and regulators."
- "... movement of control toward the supplier, but still leaves the responsibility for the data and process with the regulated company supplier."

Suggested approach:

- Cost optimization should be obtained without any impact on product quality and patient safety
- A flexible risk based approach for risk identification and analysis should be used
- Manage these risk in house and as part of the supplier management processes

[GAMP Cloud Computing Special Interest Group, 2014]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment





Regulated Company manages:

- Applications

- Runtime Middleware

SaaS **PaaS laaS** Infrastructure

Vendor manages:

- Applications
 - Data
 - Runtime
 - Middleware

 - Virtualization
 - Servers
 - Storage
 - Networking

[cf. GAMP Cloud Computing Special Interest Group, 2014]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

32

Risks to non-compliance and potential auditing shortfalls **Specific Compliance & Validation**



Specific Compliance

- · Specific policies from FDA CGMP or the PIC/S with GAMP® for the validation of an SOA [Stokes, 2011] and/or Cloud Computing (partly) missing
- The current standard for SW development which was originally designed for monolithic applications - should be applied
- · GxP certification for regulated companies unfortunately does not exist [GAMP Cloud Computing Special Interest Group, 2014]

Validation

- · A flexible and Risk-based approach can be used [Stokes, 2011; Reid, 2012]
- · Recommendations on how to assess the risks, identify gaps and provide guidelines for the changing landscape of IT controls will follow ... [cf. GAMP Cloud Computing Special Interest Group, 2014]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

FDA's Viewpoint on Cloud Computing



What are regulators interested in when they discover IT is outsourced?

- · Integrity of the Data is assured
- · Risks clearly identified & mitigated
- Client/Provider Contracts
- · Provider Quality Systems
- · SOP's, validation, change control, training
- · Cyber security for Networked Systems
- · Data Backup/Recovery
- · Audits of Providers by FDA/Clients

[cf. Tollefsen/FDA, Reid, 2012]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

34

Topics, Definitions and State of the Art

Problem Statements



1. Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?

2. What is the impact on systems operation in Regulatory Affairs?

- What are the issues and concerns about data security and safety with cloud publishing solutions?
- How to define and address the risks to non- compliance and potential auditing shortfalls with cloud solutions?
- What/Which are the possibilities for linking cloud solutions and in-house hosted systems?
- Are there any performance and reliability concerns of cloud solutions in the publishing environment which should be considered? How can those be addressed?
- What are the remaining challenges for cloud solutions in publishing?

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment



Are clouds interoperable?

- At the moment not as interoperable as they could be
- Possible dependency from one service provider ("lock-in")
- · Unforeseen / unforeseeable technical errors
- · (New) Threats

Is it possible to easily change your cloud service provider?

- Probably not (due to lock-in effects and missing interoperability standards)
- · Service offerings
- · Data Disclosure
- SLAs

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Linking cloud solutions and in-house hosted systems

Current Issues




European Commission statements

- Fragmentation of the market due to differing national legal frameworks and uncertainties over applicable law, digital content and data location
- · Problems with contracts
- Standards

"jungle" of standards that generates confusion and suggests a lack of certainty as to which standards provide adequate levels of interoperability of data formats, or permit appropriate data portability.

Architecting the Cloud





3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

38

Linking cloud solutions and in-house hosted systems Service Oriented Architectures (SOA)



Facts:


- The architecture of Cloud Computing has a service-oriented basis.
- Companies which started SOA initiatives, can use Cloud Computing faster and easier.

[Schuster & Reichl, 2010]





Merging in-house applications with SaaS



[EXTEDO, 2012]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

40

Topics, Definitions and State of the Art

Problem Statements



1. Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?

2. What is the impact on systems operation in Regulatory Affairs?

- What are the issues and concerns about data security and safety with cloud publishing solutions?
- How to define and address the risks to non- compliance and potential auditing shortfalls with cloud solutions?
- What/Which are the possibilities for linking cloud solutions and in-house hosted systems?
- Are there any performance and reliability concerns of cloud solutions in the publishing environment which should be considered? How can those be addressed?
- What are the remaining challenges for cloud solutions in publishing?

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Premises



Technical / Network Infrastructure

- Bandwidth
- · Connectivity between/from locations/countries
- Systems integration opportunities (on-premise with Cloud)

Specific SLA's

- Responsibility for application management and performance with the service provider
- · Responsibility for data integrity and security with service provider
- Responsibility for Privacy (e.g. Data Processing Agreement)
- · Availability, business continuity / disaster recovery
- · Management of service change or contract exit
- · Service provider business failure

Premises

 The basic premises do not change in an outsourced environment – what changes is the chain of command and trust [Reid, 2012]

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

42

Topics, Definitions and State of the Art

Problem Statements



1. Could Cloud Computing lead to a decisive change in the way business software is deployed in pharmaceutical companies?

2. What is the impact on systems operation in Regulatory Affairs?

- What are the issues and concerns about data security and safety with cloud publishing solutions?
- How to define and address the risks to non- compliance and potential auditing shortfalls with cloud solutions?
- What/Which are the possibilities for linking cloud solutions and in-house hosted systems?
- Are there any performance and reliability concerns of cloud solutions in the publishing environment which should be considered? How can those be addressed?
- What are the remaining challenges for cloud solutions in publishing?

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

Legislation and Compliance



Consider legislation and regulatory requirements for certain countries and industries

- · Data Privacy / EU and national legislations
- · Moving data to the cloud is not always allowed

Understand Compliance Requirements

 Lack of control over the individual services (Web/Cloud Services, as well as concerns about the compliance of quality standards

[Stokes, 2011]

· Risk Analysis is a must!

Consider GAMP® and cross industry guides

 e.g. ISO 27001, ITIL, CMMi on Application and Infrastructure Development, Validation / Qualification, Operation, Support and Retirement

Plan on legal advice!

Perform Pilot Projects!

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

45

Conclusions

Potential Benefits



'Good Practice'

Development of cloud computing systems relies on input from all organizations using the services

Fast Deployment

New functionality in e.g. eSubmisson System becomes available to the organization fast

Performance, Scalability & Availability

Conformance with changing demands

Dynamic load balancing

Cost volatility

Pay as you go

SLA-approach with fixed service level, fixed fee, fixed duration of contract

Convenience

80% of needs are identical, standard will be 'good enough'!

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

References or Bibliographies (1/3)



- Ahson, S.A. & Ilyas, M. (2011): Cloud Computing and Software Services Theory and Techniques. CRC Press
- Armbrust, M. et al. (2010): Clearing the clouds away from the true potential and obstacles posed by this computing capability, Communications of the ACM, Vol. 53, No. 4
- Avanade (2011): Global Survey: Has Cloud Computing Matured? <u>Third Annual Report, June 2011</u>
- Castro, D. (2013): How Much Will PRISM Cost the U.S. Cloud Computing Industry?, The Information Technology & Innovation Foundation, http://www2.itif.org/2013-cloud-computing-costs.pdf
- CSA (2011): Security Guidance for Critical Areas of Focus in Cloud Computing V3.0, Cloud Security Alliance
- European Commission (2012): Unleashing the Potential of Cloud Computing in Europe What is it and what does it mean for me?, MEMO/12/713, 27/09/2012
- FEI (2013): Cloud Adoption, Usage Increases, Financial Executive International, Oct. 2013
- Forrester Research (2011): "The Top 10 Technology Trends EA Should Watch: 2012 To 2014"
- · Fogh Ho-Lanng, K. (2010): Cloud Computing, DIA, Nice
- GAMP Cloud Computing Special Interest Group (2014): Cloud Computing in a GxP Environment: The Promise, the Reality and the Path to Clarity, Pharmaceutical Engineering, Vol. 34, No. 1

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

47

References or Bibliographies (2/3)



- Gartner (2011): Gartner Executive Programs Worldwide Survey of More Than 2,000 ClOs Identifies Cloud Computing as Top Technology Priority for ClOs in 2011
- Gartner Hype Cycle for Emerging Technologies, 2012, http://www.gartner.com/technology/research/hype-cycles/
- Gens, S. & Brolund, G. (2013): Managing Regulatory Information as a Corporate Asset Industry, Health Authority, and Vendor Trends, Gens and Associates RIM White Paper, Fall 2013
- Gebauer, J., & Fei, L. (02 2008). Enterprise system flexibility and implementation strategies: aligning theory with evidence from a case study in: Information Systems Management (Volume 25 Issue 1), S. 71-82.
- Giebichenstein, R./Weiss, A. (2011): Zertifizierte Cloud durch das EuroCloud Star Audit SaaS, DuD 2011, 338.
- Handelsblatt (2011): Mit Cloud Computing gegen Krebs und Alzheimer"), 16.06.2011, http://www.handelsblatt.com/technologie/it-tk/special-cloud-computing/mit-cloud-computing- gegen-krebs-und-alzheimer/4289308.html
- IDC (2011): Innovationsmotor Cloud Computing, IDC White Paper
- IDC (2011): Transformation der Unternehmens-IT auf dem Weg in die Cloud, Deutschland, 2011

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

References or Bibliographies (3/3)



- KPMG/BITKOM Research (2014): Cloud Monitor 2014, 30.01.2014, http://www.bitkom.org/de/presse/8477_78524.aspx
- · Mell, P. & Grance, T. (2011): The NIST Definition of Cloud Computing
- Reid, C. (2012): Operating in the Cloud, Exploring Regulatory Myths and Concerns, Qumas Connect 2012
- Schuster, F./Reichl, W. (2010): Cloud Computing und SaaS: Was sind die wirklich neuen Fragen?, CR 2010, 38.
- Skilton, M. (2010): Building Return on Investment from Cloud Computing, The Open Group
- Staten, J. (2013): The Cost of PRISM Will Be Larger Than ITIF Projects, James Staten's Blog, Forrester Research
- Stokes, D. (2011). Controlling Service Oriented Architectures in Support of Operational Improvement in: Pharmaceutical Engineering (Vol.31 No.4)
- Tsvihun, I., Stephanow, P. & Streitberger, W. (2010): Vergleich der Sicherheit traditioneller IT-Systeme und Public Cloud Computing Systeme, Fraunhofer SIT
- Wilson, F. & Bray, O. (2013): EU Data Protection Regulators and Cloud Computing Contracts, JOURNAL OF INTERNET LAW
- World Economic Forum (2014): Risk and Responsibility in a Hyperconnected World, Insight Report, Jan. 2014; Online: http://www3.weforum.org/docs/ WEF_RiskResponsibility_HyperconnectedWorld_Report_2014.pdf

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment

49

Questions







[Fotolia.de]

thomas.staedter@fom.de

3. DialogCamp

Cloud Computing in a Regulated Pharma Environment